Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

January 15, 2021January 15, 2021

Mexiletine May Lessen Motor Neuron ‘Excitability’ to Ease Cramps, Small Trial Suggests

News

Mexiletine, a heart medication used off-label to treat muscle cramps due to amyotrophic lateral sclerosis (ALS), was found to be well-tolerated and to stabilize the “hyperexcitability” of motor neurons ... Read more

January 8, 2021January 8, 2021

CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

News

Nearly half of all patients in a Phase 2 trial of CNM-Au8, Clene Nanomedicine’s lead candidate for the treatment of amyotrophic lateral sclerosis (ALS), showed improvements in the health ... Read more

January 5, 2021January 5, 2021

Extension Study Will Continue Evaluating Oral Edaravone

News

Mitsubishi Tanabe Pharma America (MTPA) has launched an extension study to assess the long-term effects of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral ... Read more

December 22, 2020December 22, 2020

4th Potential ALS Therapy, SLS-005, Added to HEALEY Platform Trial

News

A Phase 2b/3 trial investigating the potential of SLS-005 (trehalose) to slow the progression of amyotrophic lateral sclerosis (ALS) has been added to the HEALEY ALS Platform Trial, the first ... Read more

December 17, 2020December 17, 2020

AstroRx Given at Higher Dose Still Safely Slowing ALS Progression, Trial Reports

News

A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according ... Read more

July 24, 2020August 13, 2020

Gene Silencing Method Shows Promise to Treat Familial ALS Associated With SOD1 Mutations

News

A single dose of an artificial microRNA — a tiny RNA molecule that is able to control the activity of certain genes — can lower the activity of SOD1, a ... Read more

July 13, 2020July 13, 2020

2 Proteins Seen as Possible ALS Blood Biomarkers

News

Clusterin, a protein that plays a key role in motor neuron health, and ficolin-3, a protein essential for the activation of immune responses, may be promising biomarkers of amyotrophic lateral ... Read more

July 6, 2020July 29, 2020

200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy

News

Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, a cell-based therapy for people with amyotrophic lateral sclerosis (ALS), BrainStorm ... Read more

July 2, 2020July 2, 2020

Severe Weight Loss Linked to Higher Risk of Death in Study of Patients

News

Weight loss at the time of diagnosis appears common among people with amyotrophic lateral sclerosis (ALS), regardless of whether they have dysphagia or other bulbar-onset symptoms, a study looking at more than ... Read more

June 30, 2020June 30, 2020

Compound Found in Blackberries Prolongs Lifespan, Reduces Disease Severity in ALS Mice

News

Protocatechuic acid, a metabolite of one of the main substances that give blackberries and black rice their distinctive dark color, can extend the lifespan and reduce the progression and ... Read more

Pin It on Pinterest